Oncotype DX(R) Guides Individualized Treatment Decisions for More Than 100,000 Breast Cancer Patients Worldwide

Market Wire, May, 2009

Links to third-party websites or pages are provided for convenience only. Each website is subject to its own terms of use, and we encourage you to consult these policy statements. Genomic Health has no control over third party sites and does not endorse or recommend these sites, and expressly disclaims any responsibility for the accuracy of content or opinions set forth in any third party website or your use of that information. In addition, Genomic Health disclaims all liability arising out of allegations that third party content infringes the intellectual property rights of any person. Information in this release should not be considered medical advice. Patients should consult their doctor to determine the appropriate treatment decision for their individual disease.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=991369

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contacts: Investors: Brad Cole Genomic Health 650-569-2281 Email Contact Media: Emily Faucette Genomic Health 650-569-2824 Email Contact

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
Click Here
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Market Wire